JP2000509999A - レンチウイルスから誘導した非相同挿入部分を含むポックスウイルスベースの発現ベクター - Google Patents
レンチウイルスから誘導した非相同挿入部分を含むポックスウイルスベースの発現ベクターInfo
- Publication number
- JP2000509999A JP2000509999A JP10522713A JP52271398A JP2000509999A JP 2000509999 A JP2000509999 A JP 2000509999A JP 10522713 A JP10522713 A JP 10522713A JP 52271398 A JP52271398 A JP 52271398A JP 2000509999 A JP2000509999 A JP 2000509999A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- fiv
- vector
- gag
- env
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000713666 Lentivirus Species 0.000 title claims abstract description 68
- 238000003780 insertion Methods 0.000 title description 35
- 230000037431 insertion Effects 0.000 title description 34
- 239000013604 expression vector Substances 0.000 title description 6
- 241000700605 Viruses Species 0.000 claims abstract description 180
- 241000713800 Feline immunodeficiency virus Species 0.000 claims abstract description 176
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 120
- 239000000203 mixture Substances 0.000 claims abstract description 102
- 230000014509 gene expression Effects 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 78
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims abstract description 67
- 239000004365 Protease Substances 0.000 claims abstract description 61
- 108091007433 antigens Proteins 0.000 claims abstract description 51
- 102000036639 antigens Human genes 0.000 claims abstract description 50
- 239000000427 antigen Substances 0.000 claims abstract description 47
- 230000028993 immune response Effects 0.000 claims abstract description 40
- 241000178270 Canarypox virus Species 0.000 claims abstract description 21
- 230000002238 attenuated effect Effects 0.000 claims abstract description 17
- 239000013598 vector Substances 0.000 claims description 157
- 210000004027 cell Anatomy 0.000 claims description 122
- 108020004414 DNA Proteins 0.000 claims description 62
- 229960005486 vaccine Drugs 0.000 claims description 62
- 239000013612 plasmid Substances 0.000 claims description 49
- 241001465754 Metazoa Species 0.000 claims description 32
- 241000700618 Vaccinia virus Species 0.000 claims description 32
- 230000001900 immune effect Effects 0.000 claims description 21
- 241000282414 Homo sapiens Species 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 13
- 108091029865 Exogenous DNA Proteins 0.000 claims description 11
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- 241001529453 unidentified herpesvirus Species 0.000 claims description 10
- 241000282412 Homo Species 0.000 claims description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 9
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 8
- 238000009739 binding Methods 0.000 claims description 8
- 241000700662 Fowlpox virus Species 0.000 claims description 7
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- -1 or EnV Proteins 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 101710177291 Gag polyprotein Proteins 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 101000798869 Escherichia phage Mu DDE-recombinase A Proteins 0.000 claims 1
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 241000713325 Visna/maedi virus Species 0.000 claims 1
- 210000003837 chick embryo Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003208 petroleum Substances 0.000 claims 1
- 241000282326 Felis catus Species 0.000 abstract description 69
- 108091005804 Peptidases Proteins 0.000 abstract description 47
- 241001430294 unidentified retrovirus Species 0.000 abstract description 40
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract description 35
- 206010061598 Immunodeficiency Diseases 0.000 abstract description 34
- 230000007813 immunodeficiency Effects 0.000 abstract description 33
- 230000003053 immunization Effects 0.000 abstract description 29
- 238000002649 immunization Methods 0.000 abstract description 29
- 230000001681 protective effect Effects 0.000 abstract description 29
- 230000006698 induction Effects 0.000 abstract description 20
- 230000005847 immunogenicity Effects 0.000 abstract description 10
- 239000000523 sample Substances 0.000 abstract description 10
- 229940030156 cell vaccine Drugs 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000037452 priming Effects 0.000 abstract description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 92
- 102000004169 proteins and genes Human genes 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 61
- 108091026890 Coding region Proteins 0.000 description 42
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 38
- 210000002966 serum Anatomy 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 208000015181 infectious disease Diseases 0.000 description 29
- 206010046865 Vaccinia virus infection Diseases 0.000 description 27
- 208000007089 vaccinia Diseases 0.000 description 27
- 241000725303 Human immunodeficiency virus Species 0.000 description 25
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 24
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 24
- 241000713311 Simian immunodeficiency virus Species 0.000 description 24
- 230000006870 function Effects 0.000 description 22
- 230000004044 response Effects 0.000 description 22
- 206010070834 Sensitisation Diseases 0.000 description 21
- 230000037433 frameshift Effects 0.000 description 21
- 230000008313 sensitization Effects 0.000 description 21
- 230000036039 immunity Effects 0.000 description 20
- 230000002163 immunogen Effects 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 230000006798 recombination Effects 0.000 description 20
- 238000005215 recombination Methods 0.000 description 18
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 108020004705 Codon Proteins 0.000 description 15
- 102100034349 Integrase Human genes 0.000 description 15
- 238000012217 deletion Methods 0.000 description 15
- 230000037430 deletion Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 108700026244 Open Reading Frames Proteins 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000011081 inoculation Methods 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 241000271566 Aves Species 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 11
- 108020004440 Thymidine kinase Proteins 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 241000701447 unidentified baculovirus Species 0.000 description 11
- 108091081024 Start codon Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 241000710929 Alphavirus Species 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 102000006601 Thymidine Kinase Human genes 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000008030 elimination Effects 0.000 description 8
- 238000003379 elimination reaction Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000007758 minimum essential medium Substances 0.000 description 8
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 230000005867 T cell response Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241000991587 Enterovirus C Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010037742 Rabies Diseases 0.000 description 5
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 5
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 5
- 101710188106 SEC14-like protein 2 Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 101710121417 Envelope glycoprotein Proteins 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 101150039660 HA gene Proteins 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000007917 intracranial administration Methods 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 101150084229 ATXN1 gene Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700663 Avipoxvirus Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010034516 FIV protease Proteins 0.000 description 3
- 241000282324 Felis Species 0.000 description 3
- 208000000666 Fowlpox Diseases 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 201000003740 cowpox Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940023064 escherichia coli Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 2
- 101150039990 B13R gene Proteins 0.000 description 2
- 101150068401 BSL1 gene Proteins 0.000 description 2
- 102100038909 Caveolin-2 Human genes 0.000 description 2
- 241000700626 Cowpox virus Species 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 108700030373 Feline immunodeficiency virus p24 Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 2
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000208474 Protea Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 101150071286 SPI-2 gene Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 101800000385 Transmembrane protein Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700622 Vaccinia virus Copenhagen Species 0.000 description 2
- 241000700646 Vaccinia virus WR Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- POFWRMVFWIJXHP-UHFFFAOYSA-N n-benzyl-9-(oxan-2-yl)purin-6-amine Chemical compound C=1C=CC=CC=1CNC(C=1N=C2)=NC=NC=1N2C1CCCCO1 POFWRMVFWIJXHP-UHFFFAOYSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002976 reverse transcriptase assay Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000713686 Bovine lentivirus group Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 1
- 101100440696 Caenorhabditis elegans cor-1 gene Proteins 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101710172503 Chemokine-binding protein Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000621107 Enterobacteria phage N4 Probable portal protein Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010069540 Generalised vaccinia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101150080862 NA gene Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241001024099 Olla Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- 101710138270 PspA protein Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000288960 Saguinus oedipus Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 101100534084 Vaccinia virus (strain Copenhagen) B14R gene Proteins 0.000 description 1
- 101100004092 Vaccinia virus (strain Western Reserve) VACWR196 gene Proteins 0.000 description 1
- 101900209501 Vaccinia virus Thymidine kinase Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 108700003816 citrullinated- EBNA-2 protein (338-358) Proteins 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000407 epitaxy Methods 0.000 description 1
- 208000009724 equine infectious anemia Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 108700010758 gag-pro Proteins 0.000 description 1
- 101150081889 gag-pro gene Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- LIAWOTKNAVAKCX-UHFFFAOYSA-N hydrazine;dihydrochloride Chemical compound Cl.Cl.NN LIAWOTKNAVAKCX-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000000710 polymer precipitation Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 244000239635 ulla Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 208000014016 variola minor infection Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.少なくとも1個のレンチウイルスエピトープをコードする外因性DNAを含 むベクター。 2.ベクターがウイルスである請求項1に記載のベクター。 3.ウイルスがポックスウイルス、アデノウイルス、あるいはヘルペスウイルス である請求項2に記載のベクター。 4.ヘルペスウイルスがネコヘルペスウイルスベクターである請求項3に記載の ベクター。 5.ポックスウイルスがワクシニアウイルスである請求項3に記載のベクター。 6.ワクシニアウイルスがNYVAC株である請求項5に記載のベクター。 7.ポックスウイルスがカナリア痘ウイルスである請求項3に記載のベクター。 8.カナリア痘ウイルスがALVAC株であるか、もしくはヒナ胚線維芽細胞で 200代以上の連続継代を通して弱毒化し、そのマスターシードを寒天下で4回 連続的にプラーク精製して、そのプラーククローンを5代の追加継代を通して増 幅したレンツェラーワクチン株である、請求項7に記載のベクター。 9.ポックスウイルスが鶏痘ウイルスである請求項3に記載のベクター。 10.鶏痘ウイルスがTROVAC株である請求項9に記載のベクター。 11.ベクターが裸のあるいは製剤されたDNAプラスミドである請求項1に記 載のベクター。 12.レンチウイルスがHIV‐1である請求項1に記載のベクター。 13.レンチウイルスがHIV‐2である請求項2に記載のベクター。 14.レンチウイルスがBIVである請求項1に記載のベクター。 15.レンチウイルスがFIVである請求項1に記載のベクター。 16.レンチウイルスがEIAVである請求項1に記載のベクター。 17.レンチウイルスがビスナウイルスである請求項1に記載のベクター。 18.レンチウイルスがヤギ関節炎‐脳脊髄炎ウイルスである請求項1に記載の ベクター。 19.DNAがGag‐Pol、Gag‐プロテアーゼまたはEnv、Gag‐ Pol、あるいはEnv、Gag‐プロテアーゼの全部あるいは一部をコードす る、請求項1から18のいずれか一つに記載のベクター。 20.DNAがGag‐PolあるいはGag‐プロテアーゼの全部あるいは一 部をコードする、請求項1から18のいずれか一つに記載のベクター。 21.DNAがEnv、Gag‐Pol、あるいはEnV、Gag‐プロテアー ゼの全部あるいは一部をコードする、請求項1から18のいずれか一つに記載の ベクター。 22.vCP242、vCP253、vCP255、あるいはvCP329であ る請求項15に記載のベクター。 23.動物あるいはヒトにおいて免疫学的治療あるいは免疫応答を誘発すること を必要とする動物あるいはヒトを治療するための、請求項1から18のいずれか 一つに記載されているようなベクターを含む組成を適当な担体と混合して前記の 動物あるいはヒトに投与することを含む方法。 24.動物あるいはヒトにおいて免疫学的治療あるいは免疫応答を誘発すること を必要とする動物あるいはヒトを治療するための、請求項20に記載のベクター を含む組成を適当な担体と混合して前記の動物あるいはヒトに投与することを含 む方法。 25.動物あるいはヒトにおいて免疫学的治療あるいは免疫応答を誘発すること を必要とする動物あるいはヒトを治療するための、請求項21に記載のベクター を含む組成を適当な担体と混合して前記の動物あるいはヒトに投与することを含 む方法。 26.当該方法がプライム‐ブースト処方であり、さらに当該組成の投与前ある いは投与後のいずれかに各々のレンチウイルスエピトープあるいは各々の不活性 化レン チウイルスを追加的に投与することを含む、請求項23に記載の方法。 27.当該方法がプライム‐ブースト処方であり、さらに当該組成の投与前ある いは投与後のいずれかに各々のレンチウイルスエピトープあるいは各々の不活性 化レンチウイルスを追加的に投与することを含む、請求項24に記載の方法。 28.当該方法がプライム‐ブースト処方であり、さらに当該組成の投与前ある いは投与後のいずれかに各々のレンチウイルスエピトープあるいは各々の不活性 化レンチウイルスを追加的に投与することを含む、請求項25に記載の方法。 29.請求項1から18のいずれか一つに記載されているようなベクターを適当 な担体と混合して含む、免疫応答を誘発するための組成。 30.請求項20に記載されているようなベクターを適当な担体と混合して含む 、免疫応答を誘発するための組成。 31.請求項21に記載されているようなベクターを適当な担体と混合して含む 、免疫応答を誘発するための組成。 32.請求項1から18にいずれか一つに記載されているようなベクターを細胞 に導入することを含む、in vitroで培養した細胞において遺伝子産物を 発現するための方法。 33.請求項15から22のいずれか一つに記載されているようなウイルスのi n vitroでの発現から調製されるネコ免疫不全ウイルス抗原。 34.請求項1から18のいずれか一つに記載されているようなベクターからの 抗原のin vivoでの発現によって、あるいは当該ベクターのin vit roでの発現からのレンチウイルス結合抗原の投与によって誘発される抗体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/746,668 | 1996-11-14 | ||
US08/746,668 US7255862B1 (en) | 1996-11-14 | 1996-11-14 | ALVAC/FIV constructs |
PCT/US1997/020430 WO1998021354A1 (en) | 1996-11-14 | 1997-11-07 | Poxvirus-based expression vectors containing heterologous inserts derived from lentiviruses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003081436A Division JP3936303B2 (ja) | 1996-11-14 | 2003-03-24 | レンチウイルスから誘導した非相同挿入部分を含むポックスウイルスベースの発現ベクター |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000509999A true JP2000509999A (ja) | 2000-08-08 |
JP4064466B2 JP4064466B2 (ja) | 2008-03-19 |
Family
ID=25001826
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52271398A Expired - Lifetime JP4064466B2 (ja) | 1996-11-14 | 1997-11-07 | レンチウイルスから誘導した非相同挿入部分を含むポックスウイルスベースの発現ベクター |
JP2003081436A Expired - Lifetime JP3936303B2 (ja) | 1996-11-14 | 2003-03-24 | レンチウイルスから誘導した非相同挿入部分を含むポックスウイルスベースの発現ベクター |
JP2006277013A Pending JP2007001990A (ja) | 1996-11-14 | 2006-10-10 | ワクチン |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003081436A Expired - Lifetime JP3936303B2 (ja) | 1996-11-14 | 2003-03-24 | レンチウイルスから誘導した非相同挿入部分を含むポックスウイルスベースの発現ベクター |
JP2006277013A Pending JP2007001990A (ja) | 1996-11-14 | 2006-10-10 | ワクチン |
Country Status (12)
Country | Link |
---|---|
US (1) | US7255862B1 (ja) |
EP (1) | EP0956360B1 (ja) |
JP (3) | JP4064466B2 (ja) |
AT (1) | ATE330023T1 (ja) |
AU (1) | AU733079B2 (ja) |
CA (1) | CA2271955C (ja) |
DE (1) | DE69736126T2 (ja) |
DK (1) | DK0956360T3 (ja) |
ES (1) | ES2267154T3 (ja) |
NO (1) | NO992369L (ja) |
PT (1) | PT956360E (ja) |
WO (1) | WO1998021354A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004533208A (ja) * | 2000-08-14 | 2004-11-04 | アメリカ合衆国 | 遺伝的免疫化のための免疫原性を強化するHIVEnv、Gag、およびPolの改変 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7255862B1 (en) * | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
GB2345062B (en) * | 1997-12-22 | 2001-07-25 | Oxford Biomedica Ltd | Retroviral vectors |
EP1074625A3 (en) | 1999-06-14 | 2002-01-02 | Pfizer Products Inc. | DNA vaccine against feline immunodeficiency virus |
FR2796397B1 (fr) * | 1999-07-16 | 2006-09-01 | Merial Sas | Genes de calicivirus felin et vaccins notamment vaccins recombines |
US6541458B1 (en) | 1999-07-16 | 2003-04-01 | Merial | Feline calicivirus genes and vaccines in particular recombinant vaccines |
FR2796396A1 (fr) * | 1999-07-16 | 2001-01-19 | Merial Sas | Gene de calicivirus felin et vaccin recombine les incorporant |
EP1964573B1 (en) * | 1999-10-22 | 2014-11-26 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
US7851212B2 (en) * | 2000-05-10 | 2010-12-14 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
CU23235A1 (es) * | 2001-02-28 | 2007-09-26 | Ct Ingenieria Genetica Biotech | POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA |
FR2825280B1 (fr) * | 2001-06-01 | 2005-04-15 | Merial Sas | Vaccination contre le virus de l'immunodeficience feline |
US20040223949A1 (en) * | 2002-10-22 | 2004-11-11 | Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. | Vaccines using high-dose cytokines |
US20060257416A1 (en) * | 2003-06-13 | 2006-11-16 | Palmowski J M | Materials and methods for improved vaccination |
WO2007136763A2 (en) * | 2006-05-19 | 2007-11-29 | Sanofi Pasteur, Inc. | Immunological composition |
GB2460694A (en) * | 2008-06-06 | 2009-12-09 | Secr Defence | Attenuated poxviruses |
EP2424999A1 (en) | 2009-04-30 | 2012-03-07 | Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) | Modified immunization vectors |
GB201006405D0 (en) * | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
KR20160101073A (ko) | 2013-12-20 | 2016-08-24 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
EP3268044A2 (en) | 2015-03-11 | 2018-01-17 | The Broad Institute Inc. | Prmt5 inhibitors for the treatment of cancer with reduced mtap activty |
CN116196401A (zh) | 2015-05-20 | 2023-06-02 | 博德研究所 | 共有的新抗原 |
AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
FI3580561T3 (fi) | 2017-02-12 | 2023-12-12 | Biontech Us Inc | Hla-pohjaiset menetelmät ja koostumukset sekä niiden käyttö |
TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
AU2019404547A1 (en) | 2018-12-21 | 2021-07-22 | Biontech Us Inc. | Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells |
CN116249774A (zh) | 2020-05-26 | 2023-06-09 | 迪奥尼斯治疗公司 | 核酸人工微型蛋白质组文库 |
JP2024501482A (ja) | 2020-12-14 | 2024-01-12 | ビオンテック ユーエス インコーポレイテッド | がん免疫療法のための組織特異的抗原 |
WO2023076733A1 (en) | 2021-11-01 | 2023-05-04 | Dana-Farber Cancer Institute, Inc. | Biologically selected nucleic acid artificial mini-proteome libraries |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1341439C (en) | 1987-08-26 | 2003-09-23 | Niels C. Pedersen | Feline t-lymphotropic lentivirus |
US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
JP3602530B2 (ja) * | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
US5413927A (en) | 1991-09-03 | 1995-05-09 | North Carolina State University | Feline immunodeficiency virus isolate NCSU1Lb |
US5736378A (en) * | 1991-09-12 | 1998-04-07 | The Scripps Research Institute | Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR |
JPH09512177A (ja) | 1994-04-29 | 1997-12-09 | ファルマシア・アンド・アップジョン・カンパニー | ネコ免疫不全ウイルスワクチン |
US7255862B1 (en) * | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
-
1996
- 1996-11-14 US US08/746,668 patent/US7255862B1/en not_active Expired - Fee Related
-
1997
- 1997-11-07 CA CA2271955A patent/CA2271955C/en not_active Expired - Lifetime
- 1997-11-07 DK DK97946609T patent/DK0956360T3/da active
- 1997-11-07 EP EP97946609A patent/EP0956360B1/en not_active Expired - Lifetime
- 1997-11-07 ES ES97946609T patent/ES2267154T3/es not_active Expired - Lifetime
- 1997-11-07 AU AU51745/98A patent/AU733079B2/en not_active Ceased
- 1997-11-07 WO PCT/US1997/020430 patent/WO1998021354A1/en active IP Right Grant
- 1997-11-07 JP JP52271398A patent/JP4064466B2/ja not_active Expired - Lifetime
- 1997-11-07 AT AT97946609T patent/ATE330023T1/de active
- 1997-11-07 PT PT97946609T patent/PT956360E/pt unknown
- 1997-11-07 DE DE69736126T patent/DE69736126T2/de not_active Expired - Lifetime
-
1999
- 1999-05-14 NO NO992369A patent/NO992369L/no unknown
-
2003
- 2003-03-24 JP JP2003081436A patent/JP3936303B2/ja not_active Expired - Lifetime
-
2006
- 2006-10-10 JP JP2006277013A patent/JP2007001990A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004533208A (ja) * | 2000-08-14 | 2004-11-04 | アメリカ合衆国 | 遺伝的免疫化のための免疫原性を強化するHIVEnv、Gag、およびPolの改変 |
Also Published As
Publication number | Publication date |
---|---|
NO992369L (no) | 1999-07-06 |
JP2007001990A (ja) | 2007-01-11 |
AU733079B2 (en) | 2001-05-03 |
EP0956360A1 (en) | 1999-11-17 |
PT956360E (pt) | 2006-11-30 |
NO992369D0 (no) | 1999-05-14 |
DE69736126T2 (de) | 2007-01-04 |
JP4064466B2 (ja) | 2008-03-19 |
DE69736126D1 (de) | 2006-07-27 |
DK0956360T3 (da) | 2006-10-02 |
EP0956360A4 (en) | 2003-04-23 |
WO1998021354A1 (en) | 1998-05-22 |
CA2271955A1 (en) | 1998-05-22 |
ATE330023T1 (de) | 2006-07-15 |
JP2003310286A (ja) | 2003-11-05 |
US7255862B1 (en) | 2007-08-14 |
ES2267154T3 (es) | 2007-03-01 |
EP0956360B1 (en) | 2006-06-14 |
CA2271955C (en) | 2010-08-17 |
AU5174598A (en) | 1998-06-03 |
JP3936303B2 (ja) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4064466B2 (ja) | レンチウイルスから誘導した非相同挿入部分を含むポックスウイルスベースの発現ベクター | |
Hertig et al. | Field and vaccine strains of fowlpox virus carry integrated sequences from the avian retrovirus, reticuloendotheliosis virus | |
JP4138848B2 (ja) | 免疫不全組換えポックスウイルス | |
JP5405780B2 (ja) | 発現の向上したベクター並びにその製造および使用方法 | |
KR100242671B1 (ko) | 유전학적으로 처리한 백신 균주 | |
EP0376744B1 (en) | Feline infectious peritonitis virus diagnostic tools | |
JP2001514519A (ja) | 発現が増強されたベクターならびにそれらの作出方法および用途 | |
JP2001520507A (ja) | 組換えポックスウイルス−サイトメガロウイルス組成物および使用 | |
Miyazawa et al. | Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene | |
JP2002514885A (ja) | ポックスウイルス−イヌジステンパーウイルス(cdv)組み換え体類および組成物類および前記組み換え体類を用いる方法 | |
CA2110489A1 (en) | Immunodeficiency virus recombinant poxvirus vaccine | |
JP2007105040A (ja) | 組換体ポックスウイルス−ネコ感染性腹膜炎ウイルス、その組成物およびそれらの製造および使用方法 | |
Fischer et al. | A recombinant canarypox virus protects rabbits against a lethal rabbit hemorrhagic disease virus (RHDV) challenge | |
Gilbert et al. | Feline leukemia virus envelope protein expression encoded by a recombinant vaccinia virus: apparent lack of immunogenicity in vaccinated animals | |
Van der Ryst et al. | Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes | |
JPH10512151A (ja) | Htlv抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物 | |
EP0997529B1 (en) | Feline immunodeficiency virus strain FIV-141 and uses thereof | |
Kim et al. | The role of proximal and distal sequence variations in the presentation of an immunodominant CTL epitope encoded by the ecotropic AK7 MuLV | |
AU5768501A (en) | Poxvirus-based expression vectors containing heterologous inserts derived from lentiviruses | |
KR100263279B1 (ko) | Trovac 계두 바이러스 재조합체 및 그것의 사용 | |
AU769221B2 (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
Zhou | Expression and immunogenicity of DNA vaccines containing the env and gag-pol genes of equine infectious anemia virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070416 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070419 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071120 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071227 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110111 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110111 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120111 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130111 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130111 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |